Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B

RC Schoenfeld, DL Bourdet, KA Brameld, E Chin…

Index: Schoenfeld, Ryan C.; Bourdet, David L.; Brameld, Ken A.; Chin, Elbert; De Vicente, Javier; Fung, Amy; Harris, Seth F.; Lee, Eun K.; Le Pogam, Sophie; Leveque, Vincent; Li, Jim; Lui, Alfred S.-T.; Najera, Isabel; Rajyaguru, Sonal; Sangi, Michael; Steiner, Sandra; Talamas, Francisco X.; Taygerly, Joshua P.; Zhao, Junping Journal of Medicinal Chemistry, 2013 , vol. 56, # 20 p. 8163 - 8182

Full Text: HTML

Citation Number: 17

Abstract

ABSTRACT: Hepatitis C virus (HCV) is a major global public health problem. While the current standard of care, a direct-acting antiviral (DAA) protease inhibitor taken in combination with pegylated interferon and ribavirin, represents a major advancement in recent years, an unmet medical need still exists for treatment modalities that improve upon both efficacy and tolerability. Toward those ends, much effort has continued to focus on ...